N W C J van de Donk
Overview
Explore the profile of N W C J van de Donk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
554
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Slot S, Smits K, van de Donk N, Witte B, Raymakers R, Janssen J, et al.
Bone Marrow Transplant
. 2015 Aug;
50(11):1424-31.
PMID: 26237165
In myelofibrosis, the introduction of reduced-intensity conditioning (RIC) preceding allogeneic stem cell transplantation (SCT) resulted in lower transplant-related mortality rates compared with myeloablative conditioning. However, lowering the intensity of conditioning...
12.
Nijhof I, Groen R, Lokhorst H, van Kessel B, Bloem A, van Velzen J, et al.
Leukemia
. 2015 May;
29(10):2039-49.
PMID: 25975191
Daratumumab is an anti-CD38 monoclonal antibody with lytic activity against multiple myeloma (MM) cells, including ADCC (antibody-dependent cellular cytotoxicity) and CDC (complement-dependent cytotoxicity). Owing to a marked heterogeneity of response...
13.
Franssen L, van de Donk N, Emmelot M, Roeven M, Schaap N, Dolstra H, et al.
Bone Marrow Transplant
. 2015 Mar;
50(6):822-8.
PMID: 25798669
Allo-SCT followed by DLIs can establish long-term remissions in multiple myeloma (MM) patients. In many patients, however, the immunotherapeutic graft-versus-tumor (GVT) effect is moderate and not sustained, implying that immune...
14.
van Ginkel S, Snijders T, van de Donk N, Klijn C, Broekman M
J Neurol
. 2011 Nov;
259(6):1231-3.
PMID: 22109635
No abstract available.
15.
van de Donk N, Kamps S, Mutis T, Lokhorst H
Leukemia
. 2011 Aug;
26(2):199-213.
PMID: 21852787
The introduction of autologous stem cell transplantation combined with the introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors has significantly improved survival of multiple myeloma patients. However, ultimately the majority...
16.
Minnema M, van Dorp S, van de Donk N, Schouten F, Kersten M, Coenen J, et al.
Bone Marrow Transplant
. 2010 Apr;
46(2):244-9.
PMID: 20400982
For relapsed multiple myeloma (MM) patients, allo-SCT is a possible treatment option, but recent data obtained using a nonmyeloablative (NMA) conditioning regimen are scarce. We retrospectively collected data from 38...
17.
Minnema M, van der Spek E, van de Donk N, Lokhorst H
Neth J Med
. 2010 Jan;
68(1):24-32.
PMID: 20103818
Much progress has been made in the treatment of patients with multiple myeloma (MM). The introduction of new drugs such as thalidomide, bortezomib and lenalidomide has created more possibilities for...
18.
van de Donk N, America Y, Zelissen P, Hamer B
Neth J Med
. 2009 Nov;
67(10):350-2.
PMID: 19915229
We report on a 73-year-old man with a toxic multinodular goitre, which was treated with radioiodine therapy (I-131) without pretreatment with an antithyroid drug. Four weeks later he presented with...
19.
Minnema M, van de Donk N, Zweegman S, Hegenbart U, Schonland S, Raymakers R, et al.
Bone Marrow Transplant
. 2008 Jan;
41(9):779-84.
PMID: 18195681
Recent literature suggests that after non-myeloablative allogeneic (NMA) stem cell transplantation (SCT), the incidence of extramedullary (EM) relapse in multiple myeloma (MM) patients is increased and that these relapses have...
20.
van Dorp S, Meijer E, van de Donk N, Dekker A, Nieuwenhuis K, Minnema M, et al.
Neth J Med
. 2007 May;
65(5):178-84.
PMID: 17519513
Background: The role of allogeneic stem cell transplantation in multiple myeloma is not yet established. Methods: We retrospectively evaluated the outcome of nonmyeloablative allogeneic stem cell transplantation (NMA) in patients...